CMPX insider trading
HealthcareCompass Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody for angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Company website: www.compasstherapeutics.com
CMPX insider activity at a glance
FilingIQ tracks 75 insider transactions for CMPX in filings since Jun 29, 2021. The most recent transaction is dated Oct 1, 2026.
Across the full history, 46 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CMPX insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CMPX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CMPX?
- FilingIQ tracks 75 Form 4 insider transactions for CMPX (Compass Therapeutics, Inc.), covering filings from Jun 29, 2021 onwards. 2 of those are dated within the last 90 days.
- Are CMPX insiders net buyers or net sellers?
- Across the full Form 4 history for CMPX, 46 transactions (61%) were open-market purchases and 7 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CMPX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CMPX in?
- Compass Therapeutics, Inc. (CMPX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.14B.
Methodology & sources
Every CMPX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.